Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

** This episode was originally published on June 20, 2019. It runs across cultures, through science, mathematics and art. It's as common as the branches on a tree or the layers of a Russian doll — but ...